Results 281 to 290 of about 78,184 (307)
Some of the next articles are maybe not open access.
BTK-Hemmung plus Chemotherapie
Info Onkologie, 2015In der Phase-III-Studie HELIOS wurde untersucht, ob die Kombination von Ibrutinib mit einer Chemotherapie einen zusatzlichen Vorteil fur Patienten mit rezidivierter/refraktarer CLL bietet.
openaire +1 more source
Science Signaling, 2001
The members of the Tec family of tyrosine kinases contain Src homology 2 (SH2), SH3, and pleckstrin homology (PH) domains, in addition to their kinase domains. Unlike the Src family of tyrosine kinases, which have a negative regulatory tyrosine located at their COOH-termini, members of the Tec family do not have an obvious negative ...
openaire +2 more sources
The members of the Tec family of tyrosine kinases contain Src homology 2 (SH2), SH3, and pleckstrin homology (PH) domains, in addition to their kinase domains. Unlike the Src family of tyrosine kinases, which have a negative regulatory tyrosine located at their COOH-termini, members of the Tec family do not have an obvious negative ...
openaire +2 more sources
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
Archives of Pharmacal ResearchBruton's tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved
openaire +2 more sources
Bruton's Tyrosine Kinase (Btk)
2012Bruton's tyrosine kinase (Btk) is a non-receptor tyrosine kinase belonging to the Tec family of kinases. Btk is critical for B-cell development, differentiation and signalling through the B-cell antigen receptor (BCR) as is evident by its genetic association to a human primary immunodeficiency disease known as X-linked Agammaglobulinemia (XLA).
MARK E. SCHNUTE +2 more
openaire +1 more source